I am a nuclear medicine physician with extensive and broad experience in clinical nuclear medicine. I have been practicing nuclear medicine for several years and have been involved in the day-to-day clinical use of radiopharmaceuticals for diagnosis and therapy; and in conducting and interpreting SPECT/CT, PET/CT, and nuclear cardiology studies. I am particularly interested in molecular imaging with PET/CT and in developing novel techniques to diagnose and treat cancer, particularly breast and gynecologic malignancies.
My focus is radiopharmaceutical therapy, and I am studying the use radiolabeled monoclonal antibodies to detect and treat cancers. These include: radiolabeled antibodies 8H9 and 3F8 for pediatric cancers such as metastatic neuroblastoma and brain tumors; radioimmunoPET imaging and radioimmunotherapy for renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, lymphoma, and colon cancer; and the use of peptides in diagnosing and treating neuroendocrine tumors. I am also studying the use of alpha emitters in treating bone metastasis and alpha-emitter-conjugated radiolabeled antibodies in the treatment of other malignancies. I routinely perform radiopharmaceutical therapy with 131I-MIBG for neuroendocrine tumors including neuroblastoma, pheochromocytoma, and paraganglioma; bexxar and zevalin therapy for lymphoma; and strontium or samarium radionuclides to treat metastatic bone disease pain.
I also serve as Director of the Nuclear Medicine Training Program.
- Clinical Expertise: Nuclear Medicine; PET Imaging; Targeted Cancer Therapies
- Languages Spoken: English
- Education: MD, Lady Hardinge Medical College (India)
- Residencies: Mount Sinai Medical Center (New York)
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Nuclear Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Neeta Pandit-Taskar
- A Phase III Study of Low-Dose Gemcitabine with and without 90Y-Clivatuzumab in Patients with Metastatic Pancreatic Cancer Who Have Had Two or More Prior Treatments
- A Pilot Study Assessing PET Probes to Detect Cancerous Tissue During Surgery for Recurrent Ovarian Cancer
- A Pilot Study of PET Imaging of Solid Tumors Using Radioactive Iodine-Labeled Hu3F8
- A Pilot Trial of PET Imaging with (89)Zr-DFO-Trastuzumab in Esophagogastric Cancer